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RelapseAbstract Background: Enuresis is deﬁned as a normal void occurring at an inappropriate social
time or place. The treatment approach for enuresis is controversial due to a lack of consensus as
to the exact causes of nocturnal enuresis.
Aim: Aim was to assess the efﬁcacy of desmopressin therapy in the treatment of Primary
Monosymptomatic Nocturnal Enuresis (PMNE) in Egyptian children.
Method: The study assessed 40 children aged 6–15 years suffering from PMNE. They were
divided into 2 groups; Group 1 (20 patients) were on desmopressin tablets (0.2 mg) once daily
before bedtime for 8 weeks in addition to behavioral modiﬁcations. Group 2 received only behav-
ioral modiﬁcations. Both groups were followed up for 8 weeks of treatment, and then another
8 weeks to detect relapse.
Results: The wetting frequency decreased during treatment by 70% in Group 1 and 65% in
Group 2. However, this difference was not statistically signiﬁcantly different. The complete and par-
tial response rates were 45% and 25% respectively in Group 1 and were 35% and 30% respectively
in Group 2.
Conclusion: There is a highly signiﬁcant decrease in wet nights in response to either desmopressin
or behavioral therapy. However, the difference is not statistically signiﬁcant. Also, it was found that
relapsers (mainly early relapsers) are signiﬁcantly more encountered in patients treated by desmo-
pressin.
 2015 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Primary Monosymptomatic Nocturnal Enuresis (PMNE) is
one of the most common developmental problems in children
which affects up to 20% of children at 5 years of age andnearly 1% of young adults [1]. It is deﬁned as involuntary uri-
nation while asleep after the age at which bladder control usu-
ally occurs [2]. Nocturnal enuresis is essentially benign in a
pathological sense but unfortunately it can interfere with nor-
mal development because it carries emotional stigmata [3].
Treatment of enuresis is basically on an individual basis
and decided, to a reasonable extent, on the basis of the attitude
of the child and the parents toward enuresis [3].
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the causation of nocturnal enuresis such as lack of nocturnal
vasopressin release, detrusor muscle overactivity at night and
lack of arousal from sleep, led to the proposal of various lines
of treatment such as behavioral treatment, medical treatment
like imipramine, oxybutynin, alarm therapy, hypnosis and
acupuncture [4].
Desmopressin is one of the drugs used for the treatment of
nocturnal enuresis. It is a synthetic vasopressin (V2) receptor
agonist [5].
Based on understanding the presence of lack of nocturnal
vasopressin in children with nocturnal enuresis in early 1980s
[6], desmopressin was ﬁrst licensed for the treatment of noctur-
nal polyuria in 1991 [7].
2. Subjects and methods
This study was a randomized interventional comparative
study. It was conducted at the Pediatric Psychiatry Clinic,
Pediatric Hospital, Ain Shams University. The study was con-
ducted on 40 patients aged 6–15 years (mean 9.5 ± 2.9) who
have Primary Monosymptomatic Nocturnal Enuresis
(PMNE). Eligible patients had nocturnal enuresis (non diur-
nal) and wetting frequency of 3 or more nights per week for
at least the last 2 weeks of observation.
Patients with one or more of the following were excluded
from the study; Diurnal enuresis, urinary tract infection within
the preceding 3 months, polyuric disorders (diabetes mellitus
or diabetes insipidus), abnormal urine analysis, urinary tract
abnormality, history of renal disease, hypertension or geni-
tourinary abnormality, neurological disease mental retarda-
tion or psychological disease.3. Methodology
100 patients were randomly chosen from the child psychiatry
clinic complaining of PMNE, they were stratiﬁed according
to the modality of treatment they were receiving. 20 patients
receiving desmopressin treatment plus behavioral therapy
and 20 patients on behavioral therapy only were randomly
included in the study. Each patient in this study was subjected
to the following; Full history was taken from all patients,
including; demographic data, detailed medical history, includ-
ing the presence of organic or psychological diseases, family
history of similar cases, and previous treatment which was
received.
Clinical Examination including; body measurements, physi-
cal examination, neurological examination to exclude
neurological diseases especially neural tube defects and uro-
logical examination.
Investigations; urine analysis (for all cases): To exclude the
presence of pyuria, glucosuria and diabetes insipidus. Serum
creatinine, sodium and potassium, plain X-ray spine and
EEG for some cases.3.1. Scales
3.1.1. Stanford–Binet intelligence scale [8]
An intelligence quotient or IQ is simply the ratio of mental age
(MA) to chronological age (CA) multiplied by 100:IQ ¼MA=CA 100
The Stanford–Binet intelligence scale consists of 15 subsets.
The vocabulary subset is administered ﬁrst to obtain a basal
level for beginning items in all the other subsets. The basal
level for each test was established when 2 consecutive items
are passed; the ceiling level is established by 4 consecutive
failures.
The only timed subset is pattern analysis (subset 5).
The subsets are grouped into 4 broad areas verbal reason-
ing, abstract/visual reasoning, quantitative reasoning and
short term memory and a composite score is derived from
the area scores.
The test is designed for ages 2–23 years. Administration
requires an average of 60–90 min.
After informed consent was obtained patients were divided
according to the modality of treatment they were on into 2
groups. The work has been carried out in accordance with
the code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving humans.
Group I: Patients on desmopressin tablets 0.2 mg (Minirin,
Ferring International center, Switzerland) as a treatment for
nocturnal enuresis in addition to behavioral instructions.
All children in Group 1 (20 patients) were on desmopressin
tablets once daily before bedtime for 2 months after details and
instructions about the drug and its use were given to the
patients.
Also the parents and the children were also instructed to
complete a daily voiding diary and adhere to behavioral
instructions which they were given to avoid bedwetting,
Group II: Patients of this group (20 patients) were on the
following instructions (behavioral therapy), which they were
given to avoid bedwetting, along the entire period of the
16 weeks, also they were instructed to fulﬁll a star chart to reg-
ister their voiding diaries.
3.1.2. Recommendations for the use of behavioral therapy [9]
Remove underpants and have child void in toilet at start of
every day.
 Encourage child to avoid holding urine.
 Encourage voiding at least once every 2 h, at least several
times during school day, and often enough to avoid urgency
and incontinence.
 Facilitate easy access to school toilets with a note to the
teacher.
 Have child use optimal posture to relax pelvic-ﬂoor mus-
cles, facilitating good emptying of bowel.
 Have child drink a liberal amount of water during morning
and early afternoon hours, a total of at least 30 ml per kilo-
gram of body weight.
 Minimize intake of ﬂuids and solutes after dinner unless
child is participating in evening sports or social activities.
 Encourage a daily bowel movement, preferably after break-
fast and before child leaves for school.
 Encourage the child to eat foods that soften stool and to
avoid foods that harden stool.
 Encourage the child to engage in physical activity and dis-
courage prolonged sitting in front of television or computer.
Follow up visits for both groups were scheduled every 2 weeks
to ensure adherence to the behavioral instructions and
Table 1 Comparing the number of wet nights in the two
groups at 8 and 16 weeks in relation to 0 point.
Study
groups
Time interval
(weeks)
Wet nights
Mean ± SD
t P value
Group 1 0 10.3 ± 2.7
8 2.67 ± 1.85 10.92 <0.001
16 3.67 ± 3.29 6.67 <0.001
Group 2 0 12.5 ± 2.59
8 4.2 ± 3.85 9.1 <0.001
16 4.2 ± 3.97 9.19 <0.001
Table 2 Comparing the study groups according to response at
the end of the treatment period.
Outcome Group 1
n (%)
Group 2
n (%)
v2 P value
Complete responders 9 (45%) 7 (35%) 3.16 0.37
Partial responders 5 (25%) 6 (30%)
Non responders 4 (20%) 7 (35%)
Non complaints 2 (10%) 0 (0%)
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analyze the progress of the patients.
The main variable for analysis was the average number of
wet nights per week calculated over a deﬁned period of
16 weeks.
3.2. Treatment outcomes were deﬁned as follows [10]
‘‘Complete responders’’ were patients with 1 or less wet night
per week in the last 2 weeks of treatment.
‘‘Partial responders’’ were those with more than 1 wet night
per week but greater than 50% reduction in the number of wet
nights compared with the pretreatment period.
‘‘Non-responders’’ had less than 50% reduction in wetting
frequency in the last 2 weeks of treatment. Non-compliant
patients and non-responders were considered together as
‘‘treatment failure’’.
Patients were followed for 8 weeks after cessation of treat-
ment. ‘‘Relapsers’’ were deﬁned as reappearance of >1 wet
night per week for complete responders or >50% of pretreat-
ment wetting frequency for partial responders. ‘‘Early relap-
sers’’ and ‘‘late relapsers’’ were deﬁned as those who relapsed
in the ﬁrst 4 weeks and next 4 weeks of the post-treatment
observation period, respectively.
4. Statistical analysis
Data were collected, coded, revised, veriﬁed and entered into
an IBM compatible personal computer. Data were then sta-
tistically analyzed using the statistical software package SPSS
version 12.0.
Data were summarized and the following statistical tests
were used in this study:Mean and standard deviation (SD) were
used to describe qualitative variables. Percent was used to
describe quantitative variables.
Comparison between quantitative variables was carried out
by paired student T test of two independent samples, which
were expressed in the form of P-value. Chi-square test (v2)
was used to compare qualitative variables with each other.
Analysis of variance test (ANOVA test) was used for com-
parison among different times in the same group in quantita-
tive data.
The statistical signiﬁcance of the results was assessed in the
form of P-value. Values were considered as follows:
Statistically non signiﬁcant: If P-value was >0.05,
Statistically signiﬁcant: If P-value was 60.05, Statistically
highly signiﬁcant: If P-value was 60.01 and Statistically extre-
mely signiﬁcant: If P-value was 60.001.
5. Results
This study was conducted on 40 patients aged 6–15 years
(mean age 9.5SD± 2.9) having Primary Monosymptomatic
Nocturnal Enuresis (PMNE). Patients were divided into two
equal groups; Group 1 received desmopressin and behavioral
therapy and Group 2 was on behavioral therapy only. There
was no signiﬁcant difference regarding the age, gender and
IQ level among the two study groups (P value> 0.05), i.e.
the two samples were homogenous.On comparing the number of wet nights in the two groups
at 8 and 16 weeks in relation to 0 point, it was found that wet
nights at 8 and 16 weeks in each individual group has
decreased in a highly signiﬁcant pattern in relation to wet
nights at 0 point (the beginning of the study) (Table 1).
When comparing Group 1 versus Group 2 after the treat-
ment period (First 8 weeks) it was found that the total number
of responders in the patients of Group 1 was more than that in
Group 2. However, these results were not statistically signiﬁ-
cant (P value> 0.05) (Table 2).
The wet nights in both study groups decrease greatly at the
second week as shown in Fig. 1 (this drop was more pro-
nounced in Group 1 than in Group 2 (but the difference was
not statistically signiﬁcant), reaching almost a plateau in
Group 2 till the end of the study. On the other hand, the wet
nights continue to decrease till tenth week in Group 1 (treat-
ment period) and then returned to increase starting from the
twelfth week till the end of the study.
On comparing Group 1 patients versus Group 2 patients
according to incidence of relapse it was found that (as shown
in the Fig. 2), the relapse rate in Group 1 was more than in
Group 2; The relapse rate in Group 1 was approximately
64.3%, including 35.7% early relapsers and 28.6% late relap-
sers, and 35.7% were non relapsers. On the other hand, the
relapse rate in Group 2 was 38.5%, including 30.8% early
relapsers and 7.7% late relapsers, and 61.5% were non relap-
sers. However, these differences between the two groups were
found to be non signiﬁcant statistically.
Correlation of desmopressin response with the variables in
patients data shows no signiﬁcant difference in response as
regards order of birth and number of wet nights at the begin-
ning of the study and at 16 weeks (P value> 0.05). However
there was a signiﬁcant difference in response as regards sex
i.e. males were more responders than females (P value< 0.05).
Figure 1 Showing the tracing of wet nights frequency in patients
of Group 1 and Group 2 throughout the study (treatment and
follow up periods).
Figure 2 Comparing Group 1 patients versus Group 2 patients
according to incidence of relapse.
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regards weight, height, body mass index, and IQ test (P
value> 0.05), but, there was a signiﬁcant difference in
response as regards age as older patients had a better response
(P value< 0.05).
Regarding the family history there was no signiﬁcant differ-
ence in response when correlated to the family history (P
value> 0.05).
6. Discussion
In the early eightieth of the twentieth century, it was found
that there was a lack of nocturnal vasopressin in children with
nocturnal enuresis and from then on desmopressin became an
established treatment for nocturnal enuresis [6].
The main objective of this study was to assess the efﬁcacy of
desmopressin in the treatment of PMNE in Egyptian children.
As shown in the study, the wet nights decreased in a highly sig-
niﬁcant pattern in both of the study groups. Also it was shown
that the responders in Group 1 (on desmopressin and behav-
ioral therapy) were more than the responders in Group 2
(receiving only behavioral therapy), 70% and 65% respec-
tively, but the difference was statistically non signiﬁcant. Thestatistically insigniﬁcant result comes in concordance with
[11,12].
On the other hand, many studies showed that desmopressin
is signiﬁcantly more effective than placebo in achieving dryness
[13,14].
Moffatt et al. [15] reviewed the results of all randomized
studies done in the period between 1966 and 1992 to ﬁnd out
the efﬁcacy of desmopressin. They detected 18 randomized
controlled trials which included 689 subjects. All studies found
decreased mean frequency of wetting nights ranging from 10%
to 91%, but only 24.5% of subjects achieved long-term
dryness.
Also, another study done in 2012 mentioned that the suc-
cess rates with desmopressin ranged from 10% to 65% with
relapse rate as high as 80% [16]. In most trials a response rate
of 60–70% is detected [17]. This is nearly similar to the results
of our study showing a response rate of 70% at 8 weeks and
75% at 16 weeks. This highly impressive response comes in
concordance with the study done by Cherry and SikNin [10]
who found that 70% of patients treated with desmopressin
responded to treatment including 31% complete responders
and 39% partial responders.
In the current study the responders at 8 weeks (after treat-
ment period) were 70% (45% complete responders and 25%
partial responders), however, at 16 weeks (after a short follow
up period) the responders became 75% (35% complete respon-
ders and 40% partial responders). The decrease in the number
of complete responders may be due to relapse of patients and
this led them to fall in the category of partial responders
(decrease in wet nights >50% from baseline) instead of the
category of complete responders (decrease of wet nights to
61).
Most studies found that the number of partial responders is
more than that of complete responders, for example, one study
states that 30% of responders are complete responders and
40% are partial responders [18], up to in the study done by
Matthiesen et al. [19] who found that partial responders were
100% with no complete responders at all. On the other hand,
other studies found that complete responders were more than
partial responders [20].
Therefore most studies acknowledge the efﬁcacy of desmo-
pressin, but, in some other studies it was shown that long term
results have been found to be 23% only of children treated.
This 23% is not signiﬁcantly better than spontaneous res-
olution [21].
Throughout the study period we traced the frequency of
wet nights in the patients, it was found that desmopressin have
a more rapid onset of action. However it was associated with
relapses starting to occur from the twelfth week till the end
of the study. Most studies support the rapid onset action of
desmopressin with relatively high relapse rate upon discontin-
uation [22].
In all studies it became evident that the efﬁcacy of desmo-
pressin continued or improved throughout the treatment per-
iod indicating that enuretic patients did not develop
tolerance to desmopressin, however, dose and duration of
treatment must be tailored for each patient according to symp-
toms [23].
Concerning the issue of relapse, results of the current study
showed that relapse rate was higher with desmopressin use
64.3%, in Group 1 compared to 38.5% in Group 2. These
results was in agreement with [22,15] reporting relapse rate
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treatment. The less relapse recorded in our study may be due
to the maintenance of the patients on behavioral therapy.
Another objective of the current study was to correlate the
response to desmopressin with the variable patient’s data.
When we correlated the response to desmopressin with the age
of our patients, we found that there was a signiﬁcant positive
correlation between age of the patients and their response to
desmopressin therapy. This was in agreement with [17]. On
the other hand, another study found no signiﬁcant relation
between age and response to desmopressin [24].
As regards the correlation of response to the sex of Group 1
patients, this study found that males were signiﬁcantly more
responsive than females to desmopressin after 16 weeks of
treatment and follow up. This comes in contrary with [22].
However, Butler et al. [24] found that there was no signiﬁcant
relation between response and sex.
According to order of birth of the patients, the study found
that there was a signiﬁcant relation between order of birth of
the patients and their response to desmopressin therapy after
8 weeks of treatment i.e. patients who were ﬁrst and second
in order of birth had better response than other patients who
were later in order of birth, this is probably because they are
more responsible. But Butler et al. [24] found that there was
no signiﬁcant relation between response and order of birth.
When we correlated our results with the family history of the
patients, the study found that there was no signiﬁcant relation
between family history of the patients and their response to
desmopressin therapy.
This comes in concordance with [24]. On the other hand,
Kirk et al. [25] found that those patients resistant to desmo-
pressin were more likely to have a ﬁrst degree relative with a
history of nocturnal enuresis. On the contrary, Hogg and
Husmann [26] found that responders to desmopressin have
family history of enuresis.
Regarding the IQ of the patients, the current study did not
ﬁnd any signiﬁcant relation between IQ scale of the patients
and their response to desmopressin therapy. Unfortunately
there is not much data about this issue, but it was mentioned
in one study thatmentally disabled children should have reached
a mental age of 4 years before they are considered enuretic [22].
The correlation between the response and the frequency of
wet nights/week of the patients at the beginning of the study,
detected that there was no signiﬁcant relation between baseline
wet nights per week of the patients and their response to
desmopressin therapy. This is not in agreement with Kruse
et al. who found that the best results were obtained in children
who do not wet frequently [17].
There were several limitations in this study: ﬁrstly, was the
relatively small number of the study subjects which may have
affected the results of the study.
Secondly, we studied only the short term effect of desmo-
pressin therapy (2 months) with short follow up period (only
2 months). Discontinuation of treatment and follow up after
this short time might have led to ineffective treatment or
missed relapses.
Thirdly, the lack of non treatment control group, thus we
can’t deﬁnitely exclude the possibility of spontaneous res-
olution. We didn’t include the non treatment control group
in the trial because we considered it unethical to exclude or
delay patient treatment knowing the effect of NE on the psy-
chological well being of our patients.Another limitation was that some of patients might have
dysfunctional voiding without manifesting with daytime uri-
nary symptoms [27], this would have been spotted if urody-
namic studies had been performed.
In conclusion; From this study we can conclude that desmo-
pressin is not superior to behavioral therapy in decreasing wet
nights per week in our enuretic Egyptian children. And
although it have the advantage of a more rapid onset of action
it is associated with an unfortunate higher relapse rates.
Behavioral treatment also proved to be a good monother-
apy for nocturnal enuresis, with even less relapse rate, and
more efﬁcient if combined with desmopressin.
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